Glioblastoma WHO IV spheroid cell line, NCH660h

Glioblastoma WHO IV spheroid cell line, NCH660h

Contributors

Inventor Institute
Christel Herold-Mende Heidelberg University
SKU: 162327
Product description: NCH660h is a patient-derived IDH wildtype glioblastoma neurosphere cell line established from a primary WHO grade IV tumour obtained from a 74 year old female patient. The tumour has been classified as RTKI subtype and was reported as MGMT promoter negative. Cells grow as free floating neurospheres under serum-free conditions.
Production details: Patient-derived cell line established from human tumour tissue obtained during surgical resection and expanded in vitro.
Cat. #: 162327
Cancer types: Brain cancer
Organism: Human
Tissue: Brain
Morphology: Grown as free-floating neurospheres under serum-free culture conditions.
Growth properties: Cells grow as free-floating neurospheres under serum-free conditions in non-adherent culture vessels. Cultures are maintained at 37°C in a humidified incubator with 5% CO2.
Primary citation: Dao Trong et al. 2018. Int J Mol Sci. 19(10):2903. PMID: 30257451.
Growth medium: DMEM/F-12–based serum-free medium supplemented with BIT, GlutaMAX, EGF, and FGF-2.
Subculture routine: Neurospheres are passaged at high cell density by gentle mechanical dissociation. Accutase may be used if required to obtain single-cell suspensions. Cells are reseeded in fresh serum-free medium.
Temperature: 37°C
References:

Schuster et al. 2020. Nat Commun. 11(1):6366. PMID: 33311477.

Biedermann et al. 2019. Cancers. 11(12):2028. PMID: 31888244.

Dao Trong et al. 2018. Int J Mol Sci. 19(10):2903. PMID: 30257451.

Podergajs et al. 2016. Oncotarget. 7(1):593-609. PMID: 26573230.

Hoja et al. 2016. Oncotarget. 7(39):62989-63002. PMID: 27556305.

Bougnaud et al. 2016. Oncotarget. 7(22):31955-31971. PMID: 27049916.

Campos et al. 2014. J Pathol. 234(1):23-33. PMID: 24756862.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.